The TGV-inhalonix is a biopharmaceutical company that is focused on the development of a first-in-classantibiotic to address unmet needs in lung infectious disease in cystic fibrosis patients in particular.

In addition to our drug development programs focused on cystic fibrosis, TGV-inhalonix has ongoing research programs aimed at other life-threatening respiratory infections.


Almost all cystic fibrosis patients from their childhood have chronic pulmonary infection that leads to accelerated decline in lung function and increased mortality.

Specifically, our  mission is to advance novel nebulized antimicrobial drug candidate Mul-1867  to treat resistant lung infections among this patient population.

TGV-inhalonix is currently organized into two areas of focus. The lead program is currently in development for the treatment of lung infections in Cystic Fibrosis patients.

The Secondary indications include lung infections in patients with chronic obstructive pulmonary disease, fugal pneumonia and ventilator-associated pneumonia.

We facilitate our efforts to bring to market our life-changing breakthroughs and to alleviate the suffering of patients affected by cystic fibrosis. We know that to make tomorrow happen for them is within our power.


Bacterial and fungal respiratory infections are the main causes of  mortality in patients with cystic fibrosis.  Inhaled antibiotics play a pivotal role in managing these infections as the drugs are delivered directly to the lungs.

Despite these advancements, much of the bacteria that cause lung infections in cystic fibrosis patients  has grown resistant to traditional antibiotics, rendering most currently available antimicrobials useless and ineffective. Furthermore, many cystic fibrosis patients develop resistant infections  and mixed bacterial-fungal infections, both of which respond poorly to antibiotc therapy. Thus, there is a critical need for the development of new broad-spectrum antimicrobials that can be effectively used to treat resistant bacteria and fungi in cystic fibrosis  patients.

TGV-inhalonix has developed a breakthrough novel drug candidate to treat these chronic and often fatal infections. Recently granted Orphan Drug Designation by the U.S. Food and Drug Administration, its candidate, Mul-1867, is the first inhaled antimicrobial being developed against multidrug-resistant bacteria and fungi in cystic fibrosis patients.